Jeffrey Daniel Bernstein - Nov 21, 2022 Form 4 Insider Report for Privia Health Group, Inc. (PRVA)

Role
Director
Signature
/s/ Jamison Yardley, attorney-in-fact
Stock symbol
PRVA
Transactions as of
Nov 21, 2022
Transactions value $
-$71,896,193
Form type
4
Date filed
11/22/2022, 05:56 PM
Previous filing
Nov 24, 2021
Next filing
May 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRVA Common Stock Sale -$71.9M -3.19M -11.38% $22.56 24.8M Nov 21, 2022 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is a managing director of Goldman Sachs & Co. LLC ("Goldman Sachs"). Goldman Sachs is a subsidiary of The Goldman Sachs Group, Inc. ("GS Group"). The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any.
F2 Pursuant to an underwriting agreement, dated November 16, 2022 (the "Underwriting Agreement"), the GS Funds (as defined below) offered and sold an aggregate 3,186,888 shares of Common Stock as set forth in the final prospectus filed by the Issuer on November 18, 2022, which offering was consummated on November 21, 2022 (the "Offering"). The amount above represents the $23.50 public offering price per share of Common Stock in the Offering less the underwriting discount of $0.94 per share of Common Stock.
F3 As of November 21, 2022, as a result of the Offering, GS Group and Goldman Sachs may be deemed to beneficially own indirectly 24,826,071 shares of Common Stock by reason of Common Stock held by certain investment entities (the "GS Funds") of which Goldman Sachs and GS Group are the general partner, managing limited partner, managing general partner, managing partner, managing member or member.